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Abstract
Background and Objective Despite its important role in
cancer treatment, there is currently very limited available
information concerning the clinical pharmacology of actino-
mycin D (Act D). The study was designed to characterise Act D
pharmacokinetics and investigate the impact of pharmacoge-
netic variation on Act D disposition in children with cancer.
Methods A total of 650 plasma samples collected over an
8 year period from 117 patients B21 years receiving Act D
(0.4–1.6 mg/m2) were used to characterise a population
pharmacokinetic model. Polymorphisms in ABCB1 were
analysed in 140 patients.
Results A 3-compartment model provided a good fit to the
data. Median values for Act D clearance and volume of
distribution in the central compartment (V1) obtained from
the model were 5.3 L/h and 1.9 L (13.9 L/h/70 kg and 7.5 L/
70 kg), respectively. There was substantial inter-subject
variation in all pharmacokinetic parameters (coefficients of
variation 53–81 % for non-normalised values). Body weight
was a major determinant of Act D clearance, such that dose
capping at 2 mg in larger children at a protocol dose of
1.5 mg/m2 resulted in significantly lower area under the
plasma concentration-time curves (mean AUC values: 9.3
versus 12.8 mgmin/L; P \ 0.0001). No significant rela-
tionships were found between ABCB1 genetic variants and
Act D pharmacokinetic parameters, nor between CL, V1 or
dose and incidence of grade 3 or 4 toxicity.
Conclusion We have defined the pharmacokinetics of Act
D in a paediatric patient population, providing robust
estimates of key pharmacokinetic parameters. Pharmaco-
kinetic data bring into question the current clinical practice
of dose capping at 2 mg in larger patients. Pharmacoge-
netic variation in candidate drug transporter genes identi-
fied from preclinical studies does not significantly impact
on Act D exposure in a clinical setting.
Key Points
We have characterised for the first time the
pharmacokinetics of actinomycin D in a large patient
population, providing robust estimates of
pharmacokinetic parameters and identifying patient
body weight as the major determinant of
actinomycin D clearance in children with cancer.
Pharmacokinetic data bring into question the clinical
utility of dose capping at 2 mg in larger children,
with significantly lower actinomycin D AUC values
observed in these patients. This issue should be
further investigated, particularly in relation to
inconsistencies in dose capping levels across clinical
trials and protocols, with actinomycin D capped at a
higher dose of 2.5 mg in the US.
Pharmacogenetic variation in ABCB1, a candidate
drug transporter gene identified from in vitro and
animal studies, does not significantly impact on
actinomycin D pharmacokinetics in children.
This work was presented in part at the 103rd Annual American
Association for Cancer Research meeting in Chicago, April 2012.
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1 Introduction
Actinomycin D (Act D) is an anti-tumour antibiotic com-
monly used in the treatment of cancer in children and
adults. As part of a multimodal approach, Act D is a key
component in the treatment of Wilms tumour, where cure
rates as high as 90 % have been achieved, rhabdomyosar-
coma and Ewings sarcoma [1]. Act D binds to DNA in a
guanine-dependent manner [2, 3], preventing the synthesis
of RNA, and has been shown to inhibit the incorporation of
nucleotide triphosphates into DNA [4].
Although treatment with Act D is often successful, one
of the main challenges associated with Act D therapy is
treatment-related hepatic toxicity or veno-occlusive dis-
ease, which occurs in up to 13.5 % of cases [5–7]. Age at
treatment is a major risk factor, with patients less than
3 years old almost fourfold more likely to have some form
of toxicity following Act D treatment as compared to
children 3–21 years of age [8]. Recently, a retrospective
study of over 3,000 patients confirmed the higher incidence
of Act D-related toxicity in patients \1 year old. Toxicity
was more likely to occur early in treatment, although the
incidence was lower in patients who tolerated their first
course of therapy [9]. Other major risk factors appear to be
the presence of Wilms tumour, as opposed to other tumour
types, and Act D dose intensity [5, 10]. Bearing these
factors in mind, it is a concern that for many well estab-
lished drugs such as Act D, currently used dosing guide-
lines are founded largely on empirical experience, as
opposed to being based on a sound knowledge of the
clinical pharmacology of the drug. Inconsistencies also
exist between clinical protocols and tumour types. For
example, dose capping of Act D at a maximum dose of
2 mg is generally employed in UK protocols, depending on
tumour type, as compared to a dose cap of 2.5 mg in US
protocols [9].
To date only one substantive paediatric patient popula-
tion has been studied, with the data obtained used in
multiple publications focusing on alternative pharmacoki-
netic modelling approaches [11, 23, 25]. The original study
of 31 patients identified a large-degree of inter-patient
variation in Act D plasma concentrations and exposure,
with a greater than fourfold range in area under the plasma
concentration-time curve (AUC0–6h) observed across the
patient population. Smaller children generally had higher
Act D AUC values and, despite the limited number of
patients, this was linked to an increased risk of toxicity.
However, this initial report was limited by low patient
numbers and only sparse pharmacokinetic sampling out to
24 h after drug administration. Although more recent
publications have reported population pharmacokinetic
models based on data from 33 and 36 children, respectively
[23, 25], in each case 31 of these patients were from the
original pharmacokinetic study carried out in the UK [11].
Due to the limited data available therefore, the determi-
nation of reliable and robust pharmacokinetic parameters
has clearly been challenging. Further characterisation of
Act D pharmacokinetics, including an influence of phar-
macogenetics, requires a significantly larger patient popu-
lation and more intensive sampling.
ATP-binding cassette (ABC) transporters such as
ABCB1, ABCC2 and ABCG2 are present at the apical
membrane in the liver, kidney and intestine where they
facilitate the removal of both endogenous and exogenous
substrates via the bile, urine and faeces [12]. These proteins
are also found at many important ‘‘sanctuary sites’’ such as
blood–brain, blood–testis, and blood–placenta barriers [13–
15]. In contrast, ABCC1 is present at the basolateral
membrane of hepatocytes and proximal tubular cells,
facilitating the export of compounds to the blood [16].
Many commonly-used anticancer drugs are substrates for
ABC transporters, which have the potential to impact drug
disposition and elimination from the body [17–21]. The
influence of drug transporters on elimination from the body
may be particularly relevant for a drug such as Act D,
which does not appear to undergo significant metabolism
[11, 22, 23].
Previously, we have demonstrated that cell lines over-
expressing ABCB1, ABCC1 or ABCC2 exhibit decreased
sensitivity to Act D as compared to the parental cell line.
Of particular note, approximately 60-fold higher concen-
tration for 50 % inhibition of cell proliferation values were
observed in MDCKII cells overexpressing ABCB1, corre-
sponding to significantly lower intracellular Act D con-
centrations. In line with these in vitro data, in vivo
knockout of Abcb1a/1b resulted in higher Act D plasma
and brain concentrations compared to those in wild-type
mice [24]. In contrast to many other established anticancer
drugs, no studies have currently been performed to inves-
tigate the impact of pharmacogenetic variation in ABCB1
on the pharmacokinetics of Act D in cancer patients.
In two large pharmacological trials conducted in the
UK, patients less than 21 years old, receiving Act D as part
of their standard treatment regimen were recruited. The
major aim of these studies was to explore the potential
influence of ABCB1 pharmacogenetic variation alongside a
more definitive characterisation of the pharmacokinetics of
Act D in children with cancer.
2 Patients and Methods
2.1 Study Population and Treatment
Study protocols were approved by the UK Trent Multi-
centre Research Ethics Committee and written informed
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consent was obtained from all patients or parents as
appropriate. Eligible patients were under 21 years of age
and were receiving Act D as part of standard chemotherapy
for a range of tumour types. The studies were registered
through the appropriate clinical trials registries (PK 2003
08-REC: 03/04/074, CTA: 23198/0001/001; PK 2006
07-REC 05/MRE04/62, CTA: 2005-002996-34, Clinical-
Trials.gov identifier: NCT00900354) before opening to
patient recruitment. Baseline toxicity data prior to Act D
treatment, including baseline haemoglobin (Hb), white
blood cell (WBC) and platelet counts, were obtained from
patients’ notes and details of concomitant medications
prior to and/or in combination with Act D were recorded.
Additional patient characteristics and clinical parameters
including glomerular filtration rate (GFR), creatinine, ALT
and bilirubin measurements were also recorded following
patient registration, i.e. prior to Act D pharmacokinetic
sampling, for post-study analysis. The type of catheter used
for Act D administration and pharmacokinetic sampling
was also recorded for all patients studied, in part to address
concerns relating to the previously reported issue of line
‘contamination’ following Act D sampling [25].
Act D was administered as a short intravenous infusion
(1–5 min) at doses of 0.4–1.6 mg/m2, with the maximum
dose capped at 2 mg for larger children. The dose of Act D
administered was adjusted for infants aged \1 year, or
weighing \10 kg in body weight, with protocol doses of
0.02–0.05 mg/kg. Toxicity following Act D treatment was
assessed by the National Cancer Institute Common Ter-
minology Criteria of Adverse Events (CTCAE v3) and
recorded for all patients over a period of three weeks fol-
lowing Act D treatment.
2.2 Blood Sampling and Analysis
Blood samples (2 mL) for measurement of Act D con-
centrations were collected in heparinised tubes from a
central venous line, prior to administration of Act D and at
5, 15 and 30 min, and 2, 4, 8, 24 and 26 h post adminis-
tration. Prior to sampling, the central venous line was flu-
shed according to a standardised procedure, to ensure
negligible contamination of the sample from the adminis-
tration fluid. This procedure included flushing the line with
10 mL saline immediately following Act D administration,
with an additional flush with 5 mL saline prior to collection
of the first Act D pharmacokinetic sample. Deadspace
volumes were also taken and discarded prior to the col-
lection of all samples for pharmacokinetic analysis. Actual
sampling times were recorded along with details of the
central line type used for sampling. Not all samples were
available for all patients and more limited pharmacokinetic
sampling was frequently carried out for smaller children.
Blood samples were immediately centrifuged at 1,200g for
10 min at 4 C. Plasma was separated and stored at
-20 C prior to analysis using a modified liquid chroma-
tography–mass spectrometry (LC–MS) assay, with a limit
of quantification of 0.25 ng/mL, as previously validated
and described [11, 22]. Briefly, extraction of clinical
samples was carried out with acetonitrile and analysis
performed on an API 4000 LC/MS/MS (AB SCIEX) using
an internal standard of 7-aminoactinomycin D. The method
has been demonstrated to exhibit good reproducibility over
a calibration curve range of 0.25–100 ng/mL, with intra-
and inter-assay precision CVs of 2.7–11.3 and 2.3–7.8 %,
respectively. Accuracy data from assay validation studies
showed relative errors of 2.0–16.4 (intra-assay) and
10.4–15.2 % (inter-assay) [22].
2.3 Pharmacogenetic Analysis
Genomic DNA was obtained from whole blood samples
using QIAamp DNA blood Maxi kits (Qiagen) according to
the manufacturer’s instructions. DNA purity and concen-
tration were measured using a NanoDrop ND-1000
(Thermo Scientific, Rockford, USA) and stored at -20 C
prior to pharmacogenetic analysis. Genotyping for ABCB1
SNPs 1236C[T (rs1128503), 3435C[T (rs1045642) and
2677G[T/A (rs2032582) was performed using TaqMan
probes and an ABI 7500 Fast Real-Time PCR System
(Applied Biosystems, CA, USA) according to manufac-
turer’s instructions. Allelic discrimination was performed
using Sequence Detection Software (Applied Biosystems,
CA, USA).
2.4 Pharmacokinetic Analysis
Using NONMEM version 7.2 [26], a population pharma-
cokinetic model was fitted to Act D plasma concentration
versus time data from a total of 650 samples obtained from
117 patients. Parameterisation of the final three compart-
ment model was in terms of systemic clearance (CL) and
central volume (V1), two inter-compartmental clearances
(Q2 and Q3) and two peripheral volumes (V2 and V3); the
ADVAN11 and TRANS3 routines were used within
NONMEM. The first order conditional estimation (FOCE)
method with g–e interaction was used to obtain parameter
estimates and bootstrap confidence intervals were also
obtained for the final model. Posthoc empirical Bayes
estimates of CL and V1 were obtained for each individual.
A VPC was carried out for the final model for which 2,000
datasets were simulated. Time following drug administra-
tion was split into 12 bins. Bootstrapping and VPC were
carried out using Perl Speaks NONMEM version 3.6.2
[27].
All population pharmacokinetic parameters were allo-
metrically scaled [28]. The exponents were fixed to 0.75
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and 1.0, for clearances and volumes respectively. Param-
eters were also scaled to a standard body weight of 70 kg
so the model for the population parameters was:
loge hi ¼ loge h þ hA loge WTi=70ð Þ
where hi is the typical value of the pharmacokinetic
parameter (CL, Q2, Q3, V1, V2 or V3) for an individual
patient, hA is the allometric exponent, WTi is patient
weight and so h is the typical value for a hypothetical 70 kg
patient. Random effects were added to pharmacokinetic
parameters as appropriate, along with covariance
parameters between these random effects. The model for
those population parameters was as follows:
loge hi ¼ loge h þ hA loge WTi=70ð Þ þ gi
where gi is the random effect for an individual patient. A
composite intra-subject error model was used initially, but
once a good model fit was obtained the additive component
was found to be unnecessary and so in the final model a
proportional intra-subject error model was utilised. Good-
ness of fit of the models was determined through exami-
nation of the NONMEM OFV, plots of individual
predictions and observed plasma concentrations against
time and examination of residuals.
2.5 Statistical Analysis
The association of covariates with CL and V1 was
assessed outside NONMEM using Stata/SE (StataCorp.
2009. Stata Statistical Software: Release 11.2. College
Station, TX: StataCorp LP) as all of the covariates con-
sidered (creatinine, C1236T, G2677T/A, C3435T, toxicity
grade, line type), with the exception of age and sex,
contained missing values. While methods for handling
missing data in non-linear mixed effects models are
available, such as multiple imputation methods, the
additional complexity entailed was not appropriate for this
analysis. Thus, unexplained variation in CL and V1 fol-
lowing allometric scaling was investigated by modelling
gCLi (etaCL) and gV1i (etaV1), reflecting the difference
between the estimated individual pharmacokinetic
parameters and the estimated population values (adjusted
for the known association between CL, V1 and body
weight). The distribution of etaCL and etaV1 was approx-
imately Gaussian and so linear regression was used to
assess the influence of continuous covariates and t-tests or
ANOVA were used for categorical covariates. Genotype
frequencies were assessed for Hardy–Weinberg equilib-
rium using the Pearson Chi-squared test. Differences in
AUC values between patients receiving a dose of 1.5 mg/
m2 as a capped versus non-capped dose were analysed by
t-test following log transformation of data.
3 Results
3.1 Patient Characteristics
One hundred and fifty-eight patients receiving Act D as
part of their standard chemotherapy regimen for various
tumour types were recruited on to the studies between
August 2004 and September 2012. The study population
had a median age of 4.6 years (range 0.3–19.8 years) and
included 78 male and 80 female patients. Wilms tumour
was the most common tumour type (48 %), followed by
rhabdomyosarcoma (30 %) and Ewing’s sarcoma (18 %).
Other tumour types included a paraspinal undifferentiated
sarcoma, an embryonal sarcoma of the liver, a pleuropul-
monary blastoma, a metastatic primitive neuroectodermal
tumour and a non-rhabdomyosarcoma tumour. Full patient
characteristics can be found in Table 1. No bias was
observed in terms of these patient characteristics when
patients were divided into groups according to availability
of pharmacokinetic data, pharmacogenetic data or both as
shown in Table 1.
3.2 Actinomycin D Pharmacokinetics
Depending on treatment protocol, doses of Act D ranged
from 0.19 to 2.5 mg (0.4–1.6 mg/m2). Out of the 158
patients recruited, blood samples for pharmacokinetic
analysis were taken from 147 patients. Quality control data
from our laboratory indicate that Act D is unstable in
human plasma when stored at -20 C for longer than six
months and as such pharmacokinetic data from 14 patients
were deemed invalid due to analysis taking place beyond
this time period. Data from a further 14 patients were
excluded due to artificially high Act D plasma concentra-
tions, several magnitudes above the range observed at early
time points following drug administration, indicative of
sample contamination. In addition, data from two patients
were excluded due to invalid assays and a single sample
from an additional patient was excluded from analysis as
the plasma concentration was below the LC–MS assay
limit of quantitation of 0.25 ng/mL.
A total of 650 plasma samples from 117 patients had a
valid analysis, and have been used to characterise the
pharmacokinetic model. Figure 1a shows individual Act D
plasma concentration (logarithmic scale) versus time data
for all patients included in the model, with a summary of
the pharmacokinetic data provided in supplementary Table
S1. This table indicates the number of samples obtained at
each study time point. Full sample sets with both early
(5–30 min) and late (20–26 h) time points were provided
by 82 patients (70 %).
A large degree of variability in plasma concentrations
was observed among the 117 patients studied. For those
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patients sampled at 5 min the median concentration was
128 lg/L (range 64.7–186 lg/L, n = 13) and for those
whose first sampling time was 15 min post administration
the median was 24.4 lg/L (5.3–122 lg/L, n = 101). The
median Act D plasma concentration in samples taken 24 h
post-administration was 1.8 lg/L (0.7–4.8 lg/L, n = 73).
3.3 Population Pharmacokinetics
A population pharmacokinetic analysis using data from
117 patients was performed using NONMEM. Act D
pharmacokinetics were characterised by a very short, rapid
elimination phase, followed by an intermediate disposition
phase and finally a slow terminal decline in plasma con-
centration, indicative of a three-compartment pharmaco-
kinetic model. Any attempt to fit a two compartment model
resulted in a poor fit and so the focus moved to three-
compartment models. Initially the model included random
effects on CL and V1 together with a covariance parameter.
Whilst this provided a reasonable fit, because of the
overriding correlation between pharmacokinetic parame-
ters and body weight, an allometrically-scaled model was
developed with fixed exponents (Model 1). This model
resulted in objective function value (OFV) drops of 773
from the comparable two-compartment model and 227
from the non-allometrically scaled three-compartment
model. Even though it provided a much-improved fit,
examination of residuals and individual fits demonstrated a
systematic lack of fit around the 4 and 6 h time points
where the model generally under-predicted Act D plasma
concentrations. Including random effects for Q3 and V3
resulted in a drop in OFV of 62 and 96, respectively and
allowing a full block covariance structure between random
effects (excluding the correlation between CL and V1)
further improved the model.
The final model (Model 2) thus contained random
effects and correlation parameters for CL, Q3 and V3, and a
further random effect for V1. This final model provided a
much-improved fit to the 4 and 6 h time points as seen in
Fig. 1b. A comparison of model parameters is shown in
supplementary Table S2, with bootstrap confidence inter-
vals for the full model shown in Table 2. Visual Predictive
Checks (VPCs) of the final model indicated that the model
provided a reliable description of the observed data
(Fig. 2). Median values of the empirical Bayes estimates of
individual pharmacokinetic parameters were: clearance
Table 1 Patient characteristics
Characteristic No of patients
(%) (n = 158)
No. of patients with valid
PK results (%) (n = 117)
No. of patients with valid
PG results (%) (n = 140)
Matched PK-PG
results (%) (n = 105)
Age (years) \1 9 (6) 9 (8) 6 (4) 6 (6)
1–3 43 (27) 30 (26) 38 (27) 27 (26)
3–10 75 (47) 54 (46) 66 (47) 49 (47)
10–21 31 (20) 24 (21) 30 (21) 23 (22)
Sex Male 78 (49) 62 (53) 71 (51) 57 (54)
Female 80 (51) 55 (47) 69 (49) 48 (46)
Weight (kg) \10 17 (11) 16 (14) 13 (9) 12 (11)
10–30 96 (61) 71 (61) 85 (61) 65 (62)
30–60 30 (19) 24 (21) 27 (19) 22 (21)
[60 7 (4) 6 (5) 7 (5) 6 (6)
Unknown 8 (5) 0 (0) 8 (6) 0 (0)
BSA (m2) \0.5 22 (14) 20 (17) 18 (13) 16 (15)
0.5–1 89 (56) 65 (56) 78 (56) 59 (56)
[1 37 (23) 31 (26) 34 (24) 29 (28)
Unknown 10 (6) 1 (1) 10 (7) 1 (1)
Diagnosis Wilms tumour 76 (48) 44 (38) 64 (46) 38 (36)
Rhabdomyosarcoma 47 (30) 44 (38) 43 (31) 40 (38)
Ewing’s sarcoma 29 (18) 24 (21) 28 (20) 23 (22)
Other 6 (4) 5 (4) 5 (4) 4 (4)
Ethnicity White British 140 (89) 103 (88) 128 (91) 97 (92)
Othera 18 (11) 14 (12) 12 (9) 8 (8)
BSA body surface area, PK pharmacokinetic, PG pharmacogenetic
a Ethnicity grouping ‘other’ includes white other (3.8 %), Asian Indian (0.6 %), Asian other (1.3 %), Black African (0.6 %), Black other
(0.6 %), mixed background (2.5 %) and other (1.3 %)
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(CL) 5.3 L/h, inter-compartmental clearance (Q2) 5.5 L/h,
inter-compartmental clearance (Q3) 13.9 L/h, central vol-
ume of distribution (V1) 1.9 L, volume of distribution of
the second compartment (V2) 4.4 L and volume of distri-
bution of the third compartment (V3) 108 L. All pharma-
cokinetic parameters had large coefficients of variation
(between 53 and 81 %) indicating substantial variation
between patients. However, the unexplained variation after
modelling was reduced to 28 % for both CL and V1.
Creatinine measurements taken immediately prior to Act
D treatment were available for 113 of the 117 patients used
in the pharmacokinetic analysis, with a median creatinine
value of 37 lmol/L (range 12–90 lmol/L). No association
of serum creatinine was found with either etaCL or etaV1.
The type of catheter used to administer Act D was inves-
tigated to address concerns relating to previously reported
line ‘contamination’ issues [25]. Although catheter type
appeared to have a minor influence on both CL and V1, this
was due to the association of line type with patient age and
thus body size. Once patient body weight had been
appropriately accounted for, the effect of line type was no
longer observed (Fig. 3).
Analysis of Act D AUC values for all patients who
received a dose of 1.5 mg/m2 showed a significantly lower
mean AUC value for larger children ([1.3 m2), where
doses were capped at 2 mg, as compared to smaller chil-
dren (B1.3 m2) where dose capping was not required
(mean AUC values: 9.3 versus 12.8 mgmin/L;
P = 0.0003) (Fig. 4).
3.4 Actinomycin D Toxicity
Act D toxicity data were available for 146 (92 %) patients.
Act D treatment was relatively well tolerated, with the most
common side-effects observed being haematological tox-
icities. Granulocytopaenia occurred in 44 % of patients,
Fig. 1 Actinomycin D plasma
concentration versus time data
for all patients (n = 117) used
in the population
pharmacokinetic analysis
(a) and individual weighted
residuals (IWRES) versus time
for population pharmacokinetic
model 2 (b). The smoothed
curves represented by dashed
lines are generated using
LOWESS (locally weighted
scatterplot smoother)
746 C. R. Hill et al.
with 35 % of patients experiencing granulocytopaenia
considered Common Toxicity Criteria (CTC) grade 3 or 4.
Grade 3 or 4 leucopenia and anaemia were seen in 26 and
16 % of patients respectively. Grade 3 or 4 infection
(15 %), thrombocytopaenia (9 %) and fever (10 %) were
also observed. Elevated alanine transaminase (ALT) and
aspartate transaminase (AST) concentrations were observed
in 8 and 4 % of patients respectively. However, only three
cases of grade 3/4 toxicity associated with liver function
were recorded. Overall, 46 patients (32 %) had no adverse
events, 62 patients (43 %) had one or more grade 1/2 tox-
icities, and 69 patients (47 %) had one or more grade 3/4
toxicities. A summary of all toxicity data is shown in sup-
plementary Table S3. No statistically significant associa-
tions were found between patient age, weight and BSA and
grade 3 or 4 treatment-related toxicities. Analysis of Act D
pharmacokinetic parameters also revealed no relationship
between CL, V1, dose or AUC and incidence of grade 3 or 4
toxicity. Any analysis of the influence of Act D pharma-
cokinetics on toxicity could be confounded by the co-
administration of other chemotherapeutics, commonly
including vincristine, ifosfamide, doxorubicin and cyclo-
phosphamide, dependent on tumour type and stage of dis-
ease. However, no clear trends were observed for particular
drug combinations in the patient population studied.
3.5 Pharmacogenetics
One hundred and forty patients provided samples for
genetic analysis. Three SNPs were analyzed in ABCB1. At
least one copy of the variant allele in three common exonic
ABCB1 SNPs, 1236C[T, 2677G[T/A and 3435C[T were
present in 44, 53 and 42 % of patients respectively. The
rare ABCB1 2677A allele, resulting in a change in amino
acid from serine to alanine, was present in 12 patients
(allele frequency 4 %). The frequencies reported for all
three SNPs were in agreement with the International
HapMap Project European Caucasian population and were
in Hardy–Weinberg equilibrium (supplementary Table S4).
Relationships between transporter genotype and key
pharmacokinetic parameters were investigated, with valid
matched pharmacokinetic and pharmacogenetic data
available from 105 patients. No associations between key
Table 2 Bootstrap estimate and confidence intervals for the final
model (Model 2)
Parameter Estimate Median 95 % Confidence
interval
CL (L/h/70 kg) 13.9 13.8 12.6–14.9
Q2 (L/h/70 kg) 15.3 15.5 10.7–21.1
Q3 (L/h/70 kg) 36.2 36.5 27.8–44.8
V1 (L/70 kg) 7.50 7.6 5.3–10.0
V2 (L/70 kg) 17.1 17.1 12.2–25.0
V3 (L/70 kg) 388 388 344–441
IIV (inter-individual variability)
CL (%CV) 28.3 28.2 23.6–34.1
V1 (%CV) 28.5 28.2 12.6–39.0
Q3 (%CV) 34.9 34.5 26.9–42.6
V3 (%CV) 41.1 40.9 31.7–50.8
Correlation
CL–Q3 0.78 0.79 0.53–0.97
CL–V3 0.75 0.74 0.49–0.97
Q3–V3 0.61 0.61 0.32–0.85
Residual %CV
18.5 18.5 16.2–20.1
CL clearance, Q2 and Q3, inter-compartmental clearance values for
compartments 2 and 3, V1 central volume of distribution, V2 and V3,
volume of distribution of the second and third compartments, CV
coefficients of variation
Fig. 2 Visual predictive check
for final model showing
observed Actinomycin D
plasma concentrations. The
solid line shows the 50th
percentile of the simulated data
and the dashed lines show the
2.5th and 97.5th percentiles.
The visual predictive check
plots obtained after stratification
by weight demonstrated a
similar level of concordance
between observed and simulated
data
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pharmacokinetic parameters including CL, V1, etaCL, or
etaV1 and ABCB1 genotype were observed (Fig. 5; sup-
plementary Table S5). Equally, there was no association
between genotype and treatment-related toxicity.
4 Discussion
Administration of Act D to paediatric patients over the last
50 years has helped to greatly improve 5 year survival
rates in Wilms tumour, rhabdomyosarcoma and Ewings
sarcoma, now standing at 85, 63 and 64 % respectively.
Despite this, toxicity associated with Act D treatment
remains a major concern and very few studies investigating
the pharmacokinetics of Act D have been published.
A previous study from our group indicated a high degree
of Act D pharmacokinetic variability in children with
cancer, but had limited patient numbers and insufficient
Fig. 3 Lack of effect of central venous catheter line-type on the
relationship between patient body weight and Actinomycin D
clearance
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sampling beyond 6 h to allow characterisation of the
appropriate pharmacokinetic model or robust estimation of
pharmacokinetic parameters [11]. Also, pharmacogenetic
studies were not appropriate in the small cohort of patients.
We now report on a larger paediatric Act D pharmacoki-
netic patient population, designed to address the limitations
of the previous study. A total of 158 patients were recruited
on to this study over an eight year period, with pharma-
cokinetic data available from 117 patients after quality
control checks. These patients represent a distinct patient
population and do not include the patients studied in the
previously published studies [11, 23]. A major goal of the
current study was to ensure that pharmacokinetic samples
were taken at both early (5–15 min) and late (20–26 h)
time points. In this study, early pharmacokinetic samples at
5 min were provided by 13 (11 %) patients and at 15 min
by 101 (86 %) patients. Full sample sets, containing both
early and late time points were available from 82 (70 %)
patients, compared to only 7 patients (23 %) in the previ-
ous study [11].
Based on pharmacokinetic samples obtained from 31
patients recruited to the original UK trial, a two-compart-
ment model initially provided the best fit to the data,
although it was clear that there were insufficient data to
characterise a third disposition phase [11]. This deficiency
was addressed to some extent by Mondick et al [23], who
added an additional two patients with more prolonged
pharmacokinetic sampling up to 48 h. However, parameter
estimates from that study would be highly dependent upon
those additional two patients. In a further elaboration, a
putative ‘line contamination’ contribution to measured
plasma concentration was modelled as a mono exponential
decay over time [25]. This was introduced in an attempt to
account for a poor fit of the model to the limited data set
available, and at most explained an additional 19 % of
variation in plasma concentrations at early time points. It
was proposed that contamination could be eliminated by an
appropriate catheter clearing procedure, such as that used
in the current study.
Using these previously published Act D pharmacoki-
netic models as a reference, pharmacokinetic data from the
117 patients were analysed to determine an appropriate
population pharmacokinetic model. In agreement with the
previous models [11, 23, 25], these data demonstrated a
very short period of rapid decline, followed by an inter-
mediate phase and then a final slow terminal decline phase,
indicative of a three compartment model. The initial
pharmacokinetic model contained random effects on CL
and V1 however a much improved fit was obtained by
incorporating fixed allometric scaling on all pharmacoki-
netic parameters (Model 1), similar to the previously
published model of Mondick et al [23]. Although this
model provided a reasonable fit at early and late time
points, it was insufficiently flexible and tended to under
predict plasma concentrations at time points between 4 and
6 h. The final model (Model 2) was obtained by incorpo-
rating additional random effects to increase the between-
subject flexibility of the model, providing a significantly
improved fit to data at all time points.
The substantially increased numbers of patients and
pharmacokinetic samples in the current study provide more
precisely estimated pharmacokinetic parameters and an
increased accuracy of population estimates. For CL
(13.9 L/h/70 kg) and V1 (7.5 L/70 kg), population esti-
mates from Model 2 were similar, but generally higher than
those presented by Edwards et al [25]. While consideration
of the ‘contamination factor’ by Edwards et al has been
proposed as having a role to play in estimating reliable Act
D pharmacokinetic parameters, by incorporating appro-
priate random effects and covariant parameters into the
model, this factor is of secondary importance to the impact
of markedly increased numbers of patients and plasma
samples available for analysis in the current study.
Empirical Bayes estimates of individual pharmacoki-
netic parameters obtained from the current model confirms
the previously reported large inter-individual variability in
Act D pharmacokinetics in children with cancer. Median
clearance was 5.3 L/h (range 1.5–23.5 L/h) with a coeffi-
cient of variation of 60 %. In contrast, the coefficient of
variation for the random effect on CL was 28 %, demon-
strating the large reduction in variability seen after
adjusting for body size by allometric scaling and con-
firming our previous conclusion that body weight is a
major determinant of Act D clearance [11].
In terms of the clinical relevance of the data obtained,
analysis of Act D AUC values for all patients who received
a dose of 1.5 mg/m2 showed a significantly lower mean
AUC value for larger patients, where doses were capped at
2 mg, as compared to smaller children receiving a dose of
1.5 mg/m2. In essence, a dose cap of 2 mg with a 1.5 mg/
m2 Act D dose means that any child with a SA [1.3 m2
will receive a lower equivalent dose. The findings from the
current study bring into question the current clinical prac-
tice of dose capping at 2 mg in these larger patients. This is
particularly the case when we consider that the standard US
dose cap for Act D is set at a dose of 2.5 mg. Indeed if this
increased dose cap had been utilised in UK patients in the
current study, the AUC values in the larger patients would
have been similar to those observed in the younger
patients. The relationship between dose capping and
reduced AUC observed in the current study would suggest
that removal of the dose cap may lead to higher and
potentially more beneficial plasma concentrations in older
patients. However, clear correlations between Act D
exposure and clinical response in children with cancer are
currently lacking.
Actinomycin D PK and PGx in children 749
Several studies have demonstrated that treatment with
Act D can cause life-threatening toxicity [5–7] and that
toxicity risk can be correlated to patient age, weight and
body size [8, 9, 11]. In the current study, Act D treatment
was relatively well-tolerated. Haematological toxicities
were by far the most common adverse effect suffered by
patients, with CTC grade 1–4 haematological toxicities
occurring in 44 % of the population. Increases in markers
of hepatotoxicity including ALT and AST were rare,
occurring in 8 and 4 % of patients respectively. Only three
patients had CTC grade 3 or 4 elevated AST or ALT,
therefore covariate comparisons were not possible. No
significant correlations were observed between pharmaco-
kinetic parameters and treatment related toxicities. In
addition, no influence of body size, dose or pharmacoki-
netic parameters were found in a comparison of patients
that experienced CTC grade 3 or 4 toxicity with those that
experienced a lower level of toxicity or no toxicity at all.
Inter-individual variation in drug exposure between
patients is a major issue, with the potential to significantly
impact on cancer therapy. This may be particularly relevant
for drugs used to treat tumours with better survival rates,
where the majority of patients respond well, but a small
percentage may experience unacceptable toxicity. Some of
this variability may be accounted for by genetic variation
in drug metabolising or transport proteins, as polymor-
phisms in these genes have the potential to alter pharma-
cokinetics and pharmacological phenotype. In vitro
investigations and studies in knock-out mice have indicated
a significant influence of ABCB1 on intracellular Act D
drug concentrations and drug disposition [24], providing a
sound rationale for hypothesising that SNPs in ABCB1 and
other transporters could influence Act D pharmacokinetics.
The relatively large paediatric patient cohort included in
the current study allowed us to investigate the potential
influence of ABCB1 genotype on the pharmacokinetics of
Act D. These studies were limited to the ABCB1 genotype
due to the convincing supportive preclinical data indicating
a role for ABCB1 in the transport of Act D [24]. The
ABCB1 SNPs 1236C[T, 2677G[T/A and 3435C[T have
been extensively studied with many anti-cancer agents,
with the results being largely inconsistent and dependent
upon drug administered and patient ethnicity. The
2677G[T/A SNP is a non-synonymous SNP, where the
variant allele T results in a serine to threonine conversion
or the variant allele A results in a serine to alanine con-
version. Both 1236C[T and 3435C[T are synonymous
SNPs, with inconsistent data concerning their effect on
ABCB1 expression and on pharmacokinetics. For example
lower digoxin exposure has been associated with TT
genotype at position 3435 [29]. Other studies have reported
better survival of glioblastoma patients with the CC
genotype treated with temozolomide [30] and higher
plasma concentrations of irinotecan in patients with a TT
genotype at position 1236 [31]. In addition breast cancer
patients who were heterozygous for each SNP had higher
overall doxorubicin exposure, whilst those patients who
were homozygous wild-type for all three SNPs had higher
clearance in an Asian patient population [19].
In the current study, no significant association was found
between ABCB1 genotype, and Act D pharmacokinetics or
treatment-related toxicities. However, bearing in mind the
overall patient numbers and relatively small numbers of
patients in certain genotype groups (most notably the TA
genotype for the 2677G[T/A polymorphism), these find-
ings do not rule out a potential influence that might be
discerned in a larger population. It is not uncommon that,
despite evidence for the functional relevance of transport
proteins in pre-clinical studies, both in vitro and in vivo,
subsequent studies in patients fail to demonstrate any
impact on pharmacokinetics. For example, the anticancer
drug docetaxel has been shown in CHO cells to be a sub-
strate for both OATP1B1 and OATP1B3 and docetaxel
clearance was 18-fold lower in Oat1b2-/- (a rodent
transporter with 60 % sequence homology to human
OATP1B1 and OATP1B3) mice. However, there was no
effect of OAT1B1 or OAT1B3 genotype on docetaxel
clearance when this was investigated in a clinical study of
141 cancer patients [32]. Our data would indicate a similar
pattern in the case of Act D, with convincing data for a
potential role of ABCB1 genotype obtained from pre-clin-
ical studies, but not substantiated in a cancer patient
population.
5 Conclusion
In summary we have defined for the first time the phar-
macokinetics of Act D in an appropriately sized paediatric
patient population, providing reliable estimates of key
pharmacokinetic parameters. The current clinical practice
of capping Act D doses at 2 mg in larger children in the
UK is brought into question by the pharmacokinetic data
obtained from this study and should be looked at in more
detail. Preliminary results would also indicate that phar-
macogenetic variation in ABCB1, a candidate drug trans-
porter gene identified from in vitro and in vivo animal
studies, does not significantly impact on Act D exposure in
children with cancer.
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